Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in New York City on Wednesday, June 3 at 2:00 p.m. EDT.
A live webcast will be available at www.retrophin.com in the Events & Presentations section. A replay of the webcast will be archived on the Retrophin website and remain accessible for at least 30 days.
About Retrophin
Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam™, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), infantile spasms, nephrotic syndrome and others. For additional information, please visit www.retrophin.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150520005825/en/
Contacts:
Chris Cline, CFA, 646-564-3680
Manager,
Investor Relations
IR@retrophin.com
